You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: LAYTON BIOSCIENCE, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  2. Identification of a Neuronal Immunosuppressive Protein

    SBC: LAYTON BIOSCIENCE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of Ntera2/D1 neurons as an alternative to embryonic neurons for transplantation therapy to ameliorate neurological deficits, currently in a Phase I trial for stroke symptoms, led to our discovery of a 40-60 kDA anionic protein with an isoelectric point of 4.8 expressed by these neurons that inhibits T-lymphocyte activa ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. INEXPENSIVE, RELIABLE BLOOD-PB ANALYZER

    SBC: Leeman Labs, Inc.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  4. Virion Solvent Treatment for SARS Vaccine Preparation

    SBC: LIPID SCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lipid Sciences, Inc., proposes to use its proprietary solvent treatment technology to develop a modified SARS viral particle to use as a prophylactic vaccine. SARS has the potential to reemerge with greater force at any time; therefore, a preventative vaccine would be highly desirable to protect both global health and economies. Our vaccine production method po ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. NOVEL BISPHOSPHONATES FOR BREAST CANCER THERAPY

    SBC: MBC Pharma, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Bisphosphonates are currently used as bone-specific palliative treatments for metastatic bone disease in multiple myeloma and breast cancer patients. However, bisphosphonate use has no proven impact on primary tumor burden and overall survival and only moderately reduces skeletal complications. Bisphosphonate conjugates were synthesized using proprietary techn ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Bisphosphonates for Multiple Myeloma Therapy

    SBC: MBC Pharma, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Bisphosphonates are currently used as bone-specific palliative treatments for the tumor-induced bone diseases observed in breast cancer and multiple myeloma patients. However, bisphosphonate use has no proven impact on primary tumor burden and overall survival and only moderately reduces skeletal complications. Bisphosphonate conjugates were synthesized using ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. PRODUCTION OF TRANSGENIC GUINEA PIGS

    SBC: Midas Biologicals, Inc.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  8. Feasibility study of a double fiber bundle dialyzer

    SBC: MIRIMEDICAL, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): Efficiency of hemodialysis is currently limited by dialyzer technology. Although new membranes with large surface areas have been developed, the increase in delivered treatment is only marginal. Double dialyzer therapies have been shown to be superior to standard high efficiency/ high flux dialysis treatments; however implementation of double dialyzer therapi ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. N/A

    SBC: MOLSOFT, LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  10. Rational Development of TCF/Beta-Catenin Antagonists

    SBC: MOLSOFT, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to discover and characterize antagonists of the association of beta-catenin with TCF/LEF-1 (T-cell factor/lymphoid enhancer factor-1), a crucial step in WNT signaling pathway. Deregulation of beta-catenin signaling was implicated in a number of malignancies, which makes beta-catenin/TCF interaction a promising target for prevention and treatment of ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government